#### Check for updates

#### **OPEN ACCESS**

EDITED BY Sandor Kerpel-Fronius, Semmelweis University, Hungary

REVIEWED BY Kata Mazalin, Boehringer Ingelheim RCV GmbH & Co KG, Austria Domenico Criscuolo,

Italian Society of Pharmaceutical Medicine, Italy \*CORRESPONDENCE

Tao Ling, Iing\_tao2022@163.com Yuejuan Zhang, zyjsxsrmyy@126.com Zhihua Tang, sxtzh@163.com

<sup>†</sup>These authors have contributed equally to this work and share first authorship

RECEIVED 09 August 2024 ACCEPTED 26 November 2024 PUBLISHED 24 December 2024

#### CITATION

Qian J, Wan J, Yao Q, Chen Y, Ling T, Zhang Y and Tang Z (2024) Cutaneous adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis. *Front. Pharmacol.* 15:1457226. doi: 10.3389/fphar.2024.1457226

#### COPYRIGHT

© 2024 Qian, Wan, Yao, Chen, Ling, Zhang and Tang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Cutaneous adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis

Junhui Qian<sup>1†</sup>, Jinlong Wan<sup>2†</sup>, Qin Yao<sup>1</sup>, Yin Chen<sup>3</sup>, Tao Ling<sup>3</sup>\*, Yuejuan Zhang<sup>1</sup>\* and Zhihua Tang<sup>1</sup>\*

<sup>1</sup>Department of Pharmacy, Shaoxing People's Hospital, Shaoxing, China, <sup>2</sup>Department of Gastroenterology, Gaozhou People's Hospital, Maoming, China, <sup>3</sup>Department of Pharmacy, Suqian First Hospital, Suqian, China

**Aim:** Cutaneous adverse events (CAEs) after treatment with BRAF and MEK inhibitors in patients with melanoma remain incompletely characterized. To determine the association of BRAF and MEK inhibitor treatment with CAEs in patients with melanoma compared with BRAF inhibitor alone.

Method: PubMed, Cochrane, Embase and Web of Science were systematically searched for BRAF and MEK inhibitors from database inception through 10 May 2024. Randomized clinical trials reporting on CAEs in patients with melanoma being treated with BRAF and MEK inhibitors compared with patients with melanoma being treated with BRAF inhibitor monotherapy were selected. Pooled Risk ratios (RRs) and 95% CIs were determined using random-effects analyses. The selected end points were alopecia, cutaneous squamous-cell hyperkeratosis, keratoacanthoma, carcinoma. palmoplantar erythrodysaesthesia syndrome, palmoplantar keratoderma, rash. photosensitivity reaction, and skin papilloma. All-grade and high-grade (≥3) CAEs were recorded.

**Results:** Comparing with BRAF and MEK inhibitors, treatment with BRAF inhibitors alone was associated with an increased risk of rash (RR, 0.73; 95% CI, 0.54–0.99; p = 0.039;  $l^2 = 88\%$ ), alopecia (RR, 0.28; 95% CI, 0.20–0.41; P < 0.001;  $l^2 = 76\%$ ), hyperkeratosis (RR, 0.30; 95% CI, 0.22–0.41; P < 0.001;  $l^2 = 56\%$ ), palmoplantar erythrodysaesthesia syndrome (RR, 0.21; 95% CI, 0.10–0.47; P < 0.001;  $l^2 = 81\%$ ), palmoplantar keratoderma (RR, 0.39; 95% CI, 0.26–0.57; P < 0.001;  $l^2 = 29\%$ ), Skin papilloma (RR, 0.25; 95% CI, 0.12–0.52; P < 0.001;  $l^2 = 77\%$ ), cutaneous squamous-cell carcinoma (RR, 0.21; 95% CI, 0.11–0.42; P < 0.001;  $l^2 = 50\%$ ), and keratoacanthoma (RR, 0.22; 95% CI, 0.12–0.40; P < 0.001;  $l^2 = 0\%$ ).

**Conclusion:** Therapy with BRAF and MEK inhibitors was associated with a lower risk of CAEs, especially rash, alopecia, hyperkeratosis, palmoplantar erythrodysaesthesia syndrome, palmoplantar keratoderma, skin papilloma, cutaneous squamous-cell carcinoma, and keratoacanthoma, compared with BRAF inhibitor alone. The risks of photosensitivity reaction was similar between the assessed groups. The findings may help to balance between beneficial melanoma treatment and cutaneous morbidity and mortality.

#### KEYWORDS

cutaneous adverse events, BRAF inhibitor, mek inhibitor, melanoma, meta analysis

## Introduction

In the Western population, 1 out of every 50 individuals will develop melanoma (Dzwierzynski, 2021). The incidence of melanoma is increasing faster than any other malignancy, and melanoma remains an important challenge to cancer control and public health globally, especially in fair-skinned populations of European descent (Arnold et al., 2022). BRAF mutations are most frequent in patients with melanoma where they occur in approximately 50% of patients with advanced disease (Yélamos et al., 2016; Davies et al., 2002). The combination of the BRAF inhibitor and MEK inhibitor showed outstanding response rates in BRAF-mutated melanoma and is now considered the standard of care in this setting (Califano et al., 2024). Combined BRAF and MEK inhibitors, as compared with BRAF inhibitors alone, should be delay the emergence of resistance and should be reduce toxic effects in patients who have melanoma with BRAF V600E or V600K mutations (Long et al., 2014).

Combined BRAF and MEK inhibitors therapy has emerged as an optimal treatment of metastatic BRAF-mutated melanoma, with improved survival rates compared with BRAF inhibitors alone (Dummer et al., 2022; Ascierto et al., 2020). Multiple studies (Hauschild et al., 2018; Long et al., 2018; Planchard et al., 2016) found that the first combined BRAF and MEK inhibitors therapy showed significant improvement in an investigator-assessed overall response and relapse-free survival in treating melanoma, which led to global approval. Up to now, 3 BRAF inhibitors [dabrafenib (Hauschild et al., 2012), vemurafenib (Chapman et al., 2011), and encorafenib (Dummer et al., 2018a)] and 3 MEK inhibitors [trametinib (Flaherty et al., 2012a), cobinimetinib (Larkin et al., 2014), and binimetinib (Ascierto et al., 2013)] have received US Food and Drug Administration and European Medicines Agency approval.

Skin manifestations are increasingly documented with anticancer drugs, which are not uncommon, and can constitute a major challenge in clinical decision making (Raschi et al., 2022; Zhao et al., 2022). Prompt recognition and multidisciplinary management are critical to prevent unnecessary discontinuation or balance timely treatment interruption with early resumption to avoid cancer recurrence or progression (Barrios et al., 2020). BRAF inhibitor with or without MEK inhibitor have been associated with dermatologic reactions, especially rash, in pivotal trials. The nature and incidence of CAEs associated with combined BRAF and MEK inhibitors therapy are incompletely described. However, cutaneous complications may affect a patient's quality of life or may require temporary or permanent cancer therapy termination. We set out to clarify the type, incidence, and Risk ratio of CAEs in patients with melanoma who are being treated with combined BRAF and MEK inhibitors therapy compared with patients receiving BRAF inhibitor alone in this systematic review and meta-analysis.

#### **Methods**

Our systematic review and meta-analysis were based on the preferred reporting items for systematic review and meta-analysis (PRISMA) guidelines (Liberati et al., 2009) and were registered in PROSPERO (CRD42024553642).

A systematic search was conducted through PubMed, Cochrane, Embase and Web of Science databases, and abstracts or presentations from annual meetings of the major cutaneous and cancer societies to identify relevant studies published from the inception of the databases to 10 May 2024, using the search terms BRAF inhibitors (dabrafenib, vemurafenib, and encorafenib) and MEK inhibitors (trametinib, cobinimetinib, and binimetinib). We considered studies published in English only. The search strategy and results of all databases are depicted in the Supplementary material. Because the purpose of this study was to summarize the incidence of overall and high-grade CAEs in patients with melanoma receiving BRAF and MEK inhibitors, we restricted our study to randomized clinical trials (RCTs) in which adult participants received the available combinations of BRAF inhibitors and MEK inhibitors (ie, dabrafenib and trametinib, vemurafenib and cobimetinib, or encorafenib and binimetinib) and were randomly assigned to a treatment or a control group. The meta-analysis excluded abstracts, reviews, animal and in vitro studies, metaanalyses, case reports, single-arm BRAF and MEK inhibitor treatment studies, monotherapy with BRAF inhibitor studies, studies with MEK inhibitor treatment with other therapies for melanoma, nonrandomized clinical trials, studies that did not report on CAEs, and special population studies (e.g., elderly population, population from a certain geographic region, pediatric population). After removing duplicates, Junhui Qian and Zhihua Tang independently reviewed the abstracts. Any discrepancies in results between the 2 investigators were solved by discussion with the other investigators (Tao Ling). When the inclusion criteria appeared to be met, the full-text publication was reviewed by the 3 authors mentioned above. At the end of the review process, the full texts of the studies considered eligible were reviewed by all investigators.

#### Data extraction and quality assessment

Junhui Qian and Zhihua Tang independently performed data extraction using a standard data extraction form that contained the following fields: (1) publication details (i.e., name of the first author and year of publication), (2) clinicalTrials.gov number, (3) study design, (4) characteristics of study population (i.e., cancer type, sample size, age, sex distribution, and ECOG PS), (5) treatment, and (6) mean follow-up.

The trial quality was assessed by Junhui Qian and Zhihua Tang for each study separately against the following criteria according to the Cochrane Risk-of-Bias Tool (Higgins and Green, 2011): (1) random sequence generation (i.e., selection bias), (2) allocation concealment (i.e., selection bias), (3) blinding of participants and personnel (ie, performance bias), (4) blinding of outcome assessment (i.e., detection bias), (5) incomplete outcome data, (6) selective reporting (i.e., reporting bias), and (7) other bias (i.e., measurement error, observer variability, dose of drug, length of follow-up, and characteristics of participants). Authors resolved disagreement by consensus, and a third author (Tao Ling) was consulted to resolve disagreement.

#### Study end points

The end points were defined according to the National Cancer Institute Common Terminology Criteria for Adverse Events version



4. All-grade and high-grade (i.e., grade 3–5, indicating severe, life threatening, or causing death) treatment-emergent CAEs were abstracted. The selected end points were as follows: (1) alopecia, (2) cutaneous squamous-cell carcinoma, (3) hyperkeratosis, (4) keratoacanthoma, (5) palmoplantar erythrodysaesthesia syndrome, (6) palmoplantar keratoderma, (7) rash, (8) photosensitivity reaction, and (9) skin papilloma.

## Statistical analysis

The meta-analysis was conducted on eligible studies by dividing the patients into the following 2 groups: (1) the BRAF and MEK inhibitors group, which included patients with melanoma treated with a combination of BRAF inhibitors and MEK inhibitors; and (2) the control group, which included patients with melanoma treated with BRAF inhibitor alone. The proportion of patients with CAEs receiving BRAF and MEK inhibitors was compared with that of the control group in the same RCT. The data are expressed as percentage of patients with CAEs, calculated by dividing the number of each CAE by the total sample size. Risk ratios (RRs) and 95% CIs are used to express dichotomous outcomes (Viera, 2008). Statistical significance was set at p < 0.05, and all tests were 2-tailed. A 2012 study (Flaherty et al., 2012b) had 3 arms: combination therapy with dabrafenib (150 mg) plus trametinib (1 or 2 mg) or dabrafenib monotherapy. A 2018 study (Dummer et al., 2018b) had 3 arms: either encorafenib plus binimetinib (encorafenib plus binimetinib group), encorafenib (encorafenib group), or vemurafenib (vemurafenib group).

For the analysis, we used random-effects. A random-effects model was preferred owing to the assumption that different studies are estimating different yet related intervention effects. In the presence of heterogeneity, the use of the random-effects method will result in wider CIs for the average intervention and corresponding claims of statistical significance will be more conservative (Higgins and Green, 2011). Statistical heterogeneity was reported as the Q statistic and I<sup>2</sup> statistics. A value of I<sup>2</sup> less than 40% denoted that heterogeneity might not be important, I<sup>2</sup> from 50% to 90% may have represented substantial heterogeneity, and I<sup>2</sup> from75% to 100% represented considerable heterogeneity (Higgins and Green, 2011). The funnel plot test could not be used to assess

Study	Clinical Trials.gov number	Туре	Cancer type	ECOG PS = 0, n (%)	Treatment	n. Of patients	Age, mean (range), y	Male, n (%)	Follow- up, median (IQR), mo	
Flaherty et al. (2012b)	NCT01072175	RCT II	Metastatic melanoma and BRAF V600 mutations	38 (70)	Dabrafenib 150 mg twice daily and trametinib 1 mg once daily	54	49 (23-85)	30 (56)	14.1 (10.8–17.6)	
				35 (65)	Dabrafenib 150 mg twice daily and trametinib 2 mg once daily	54	58 (27-79)	34 (63)		
				34 (63)	Dabrafenib 150 mg twice daily	54	50 (18-82)	29 (54)		
Robert et al. (2015)	NCT01597908	RCT III	Unresectable stage IIIC or IV melanoma with BRAF V600 mutations	248 (71)	Dabrafenib 150 mg twice daily and trametinib 2 mg once daily	352	55 (18–91)	208 (59)	10 (NA)	
				248 (70)	Vemurafenib 960 mg twice daily	352	54 (18-88)	180 (51)	11 (NA)	
Ascierto et al. (2016)	NCT01689519	RCT III	Unresectable stage IIIC or stage IV melanoma with BRAF V600 mutations	184 (76)	Vemurafenib 960 mg twice daily and cobimetinib 60 mg once daily	247	56 (23-88)	146 (59%)	14.2 (8.5–17.3)	
				164 (67)	Vemurafenib 960 mg twice daily	248	55 (25-85)	140 (56%)	>36 (NA)	
Long et al. (2017)	NCT01584648	RCT III	Unresectable stage IIIC or stage IV melanoma with BRAF V600 mutation	155 (73)	Dabrafenib 150 mg twice daily and trametinib 2 mg once daily	211	55 (22-89)	111 (53)	>36 (NA)	
				150 (71)	Dabrafenib 150 mg twice daily	212	57 (22-86)	114 (54)		
Dummer et al. (2018b)	NCT01909453	RCT III	Unresectable stage stage IIIB, IIIC, or IV, with BRAF V600 mutations	136 (71)	Encorafenib 450 mg once daily and binimetinib 45 mg twice daily	192	57 (20-89)	115 (60%)	16.6 (14.8–16.9)	
				140 (72)	Encorafenib 300 mg once daily	194	54 (23-88)	108 (56%)		
				140 (73)	Vemurafenib 960 mg twice daily	191	54 (23-88)	111 (58%)		

#### TABLE 1 Characteristics of the studies.

publication bias because our analysis included fewer than 10 studies (Higgins and Green, 2011). The analyses were conducted using R 4.4.0 and Revman 5.3.5.

# Results

## Eligible studies and characteristics

A total of 652 eligible articles were identified through database searching (Figure 1). We identified 5 RCTs of patients receiving BRAF and MEK inhibitors therapy compared with patients receiving BRAF inhibitor alone (Flaherty et al., 2012b; Dummer et al., 2018b; Robert et al., 2015; Ascierto et al., 2016; Long et al., 2017). A total of 2,361 patients with melanoma were included. General characteristics of the study population are detailed in Table 1.

## Risk ratios of all-grade CAEs

The risk of all-grade CAEs calculated as RRs are depicted in Figure 2. Comparing with BRAF and MEK inhibitors, treatment with BRAF inhibitors alone was associated with an increased risk of rash (RR, 0.73; 95% CI, 0.54–0.99; p = 0.039;  $I^2 = 88\%$ ), alopecia (RR, 0.28; 95% CI, 0.20–0.41; P < 0.001;  $I^2 = 76\%$ ), hyperkeratosis (RR, 0.30; 95% CI, 0.22–0.41; P < 0.001;  $I^2 = 56\%$ ), palmoplantar erythrodysaesthesia syndrome (RR, 0.21; 95% CI, 0.10–0.47; P < 0.001;  $I^2 = 81\%$ ), palmoplantar keratoderma (RR, 0.39; 95% CI, 0.26–0.57; P < 0.001;  $I^2 = 29\%$ ), skin papilloma (RR, 0.25; 95% CI,

begroup = Rash berry et al. 2012 (transmith 2rm) 15 54 19 53 0.57 [0.30; 1.08] the product of al. 2012 (transmith 2rm) 15 55 19 53 0.76 [0.43; 1.33] the product of al. 2015 177 247 168 246 107 [0.40; 0.44] the product of al. 2015 177 247 168 246 107 [0.46; 0.34] the product of al. 2016 (become the product of al. 2016 177 247 168 246 107 [0.46; 0.34] the product of al. 2016 (become the product of al. 2016 177 247 168 246 107 [0.46; 0.34] the product of al. 2016 (become the product of al. 2016 the product of al. 2016 (become the p	Study or Subgroup	Experimental Events Total	Control Events Total I	Risk Ratio MH, Random, 95% Cl	Risk Ratio MH, Random, 95% Cl
bigroup = Alopacia        berry et al. 2012(trametinib 2mg) 3 65 18 53 0.27 [0.11; 0.68]        bert et al. 2015 20 350. 175 349 0.15 [0.09; 0.23]        mare et al. 2016(encoratemib) 26 192 107 192 0.24 [0.17; 0.35]        mare et al. 2016(encoratemib) 26 192 107 192 0.24 [0.17; 0.35]        mare et al. 2016(encoratemib) 26 192 107 192 0.24 [0.17; 0.35]        tat [05% C) 1.299 1290 0.28 [0.20; 0.41]        tat [05% C) 1.210 129 1290 0.28 [0.20; 0.41]        tat [05% C) 1.210 129 1290 0.28 [0.20; 0.41]        tat [05% C) 1.210 129 1290 0.28 [0.20; 0.41]        tat [05% C) 1.210 129 129 1290 0.28 [0.20; 0.41]        tat [05% C) 1.210 129 129 1290 0.28 [0.20; 0.41]        tat [05% C) 1.210 129 129 1290 0.28 [0.20; 0.41]        tat [05% C) 1.210 129 1290 200 0.28 [0.20; 0.41]        tat [05% C) 1.210 129 1290 200 0.28 [0.20; 0.41]        tat [05% C) 1.210 129 129 20 0.28 [0.20; 0.41]        tat [05% C) 1.210 129 129 20 0.28 [0.20; 0.41]        tat [05% C) 1.210 129 129 120 0.28 [0.20; 0.57]        tat [05% C] 1.210 129 129 120 0.20 [0.22; 0.41]        tat [05% C] 1.210 129 129 120 0.28 [0.25; 0.45]        tat [05% C] 1.210 129 129 120 0.28 [0.25; 0.46] 1.210 120 100 120 28 [0.25; 0.41]        tat [05% C] 1.210 120 120 120 120 120 120 120 120 120	Subgroup = Rash Flaherty et al, 2012(trametinib 1mg) Flaherty et al, 2012(trametinib 2mg) Robert et al, 2015 Ascierto et al, 2016 Long et al, 2017 Dummer et al, 2018(encorafenib) Dummer et al, 2018(vemurafenib) Total (95% Cl) Heterogeneity: Tau <sup>2</sup> = 0.1225; Chi <sup>2</sup> = 4	11 54 15 55 76 350 179 247 57 209 27 192 27 192 1299 8.32, df = 6 (P <	19 53 19 53 149 349 166 246 46 211 41 192 54 186 1290 0.01); l <sup>2</sup> = 88%	0.57 [0.30; 1.08] 0.76 [0.43; 1.33] 0.51 [0.40; 0.64] 1.07 [0.96; 1.21] 1.25 [0.89; 1.75] 0.66 [0.42; 1.03] 0.48 [0.32; 0.73] 0.73 [0.54; 0.99]	
$\begin{aligned} & \text{bgroup} = \text{Hyparkeratosis} \\ & \text{aherty et al, 2012(trametinib 2mg) 5 55 16 53 0.30 [0.12; 0.76] \\ & \text{barty et al, 2015} \\ & \text{barty et al, 2016} \\ & \text{circle ot al, 2018} \\ & \text{circle ot al, 2018(renoratemb)} \\ & \text{Z} \\ & \text{192} \\ & \text{Z} \\ & \text{Z} \\ & \text{I} \\ & \text{circle ot al, 2018(renoratemb)} \\ & \text{Z} \\ & \text{192} \\ & \text{Z} \\ & \text{Z} \\ & \text{Z} \\ & \text{L} \\ & \text{def (95% C)} \\ & \text{terogeneity: Tau' = 0.1002; Chi^2 = 13.74, df = 6 (P = 0.03); l^2 = 56\% \\ \\ & \text{borroup = Palmoplantar erythrodysaesthesia syndrome bert et al, 2018(renoratemb) \\ & \text{13} \\ & \text{13} \\ & \text{13} \\ & \text{299} \\ & \text{1290} \\ & \text{1190} \\ & \text{1190} \\ & \text{1290} \\ & \text{1290} \\ & \text{1190} \\ & \text{1190} \\ & \text{1290} \\ & \text{1290} \\ & \text{1190} \\ & \text{1190} \\ & \text{1290} \\ & \text{1290} \\ & $	Subgroup = Alopecia Flaherty et al, 2012(trametinib 1mg) Flaherty et al, 2012(trametinib 2mg) Robert et al, 2015 Ascierto et al, 2016 Long et al, 2017 Dummer et al, 2018(encorafenib) Dummer et al, 2018(vemurafenib) Total (95% Cl) Heterogeneity: Tau <sup>2</sup> = 0.1676; Chi <sup>2</sup> = 2	5 54 3 55 20 350 41 247 19 209 26 192 26 192 1299 5.44, df = 6 (P <	18 53 18 53 137 349 75 246 60 211 107 192 68 186 1290 0.01); I <sup>2</sup> = 76%	$\begin{array}{c} 0.27 \; [0.11; \; 0.68] \\ 0.16 \; [0.05; \; 0.51] \\ 0.15 \; [0.09; \; 0.23] \\ 0.54 \; [0.39; \; 0.76] \\ 0.32 \; [0.20; \; 0.52] \\ 0.24 \; [0.17; \; 0.35] \\ 0.37 \; [0.25; \; 0.56] \\ 0.28 \; [0.20; \; 0.41] \end{array}$	* * * *
berroup = Palmoplantar erythrodysaesthesia syndrome        bert et al, 2015 14 350 87 349 0.16 [0.09; 0.28]        immer et al, 2018(encorafenib) 13 192 98 192 0.13 [0.08; 0.28]        immer et al, 2018(venurafenib) 13 192 26 186 0.48 [0.26; 0.91]        tat (95% Ct) 734 727 0.21 [0.10; 0.47]        terogeneity: Tau2 = 0.3847; Ch2 = 10.29, df = 2 (P = 0.01); l2 = 81%        bgroup = Palmoplantar keratoderma        mg et al, 2017 11 209 39 211 0.28 [0.15; 0.54]        immer et al, 2018(encorafenib) 17 192 29 186 0.57 [0.32; 1.00]        tat (95% Ct) 593 599 0.39 [0.26; 0.57]        terogeneity: Tau2 = 0.330; Ch2 = 2.83, df = 2 (P = 0.24); l2 = 29%        idgroup = Skin papilloma        aherty et al, 2012(trametinib 1mg) 4 54 8 53 0.49 [0.16; 1.53]        aherty et al, 2012(trametinib 2mg) 2 55 8 53 0.24 [0.05; 1.08]        bert et al, 2012(trametinib 1mg) 4 54 8 53 0.49 [0.16; 1.53]        immer et al, 2012(trametinib 2mg) 2 55 8 53 0.24 [0.05; 1.08]        bert et al, 2013(tencorafenib) 12 192 18 192 0.67 [0.33; 1.35]        immer et al, 2018(venurafenib) 12 192 198 192 0.67 [0.33; 0.10]        iterogeneity: Tau2 = 0.6167; Chl2 = 21.79, df = 5 (P = 0.01); l2 = 77%        iterogeneity: Tau2 = 0.6167; Chl2 = 21.79, df = 5 (P = 0.01); l2 = 77%        iterogeneity: Tau2 = 1.1904; Chl2 = 71.73, df = 4 (P = 0.01); l2 = 94%        tat (95% Ct) 105 13 350 78 349 0.17 [0.09; 0.29]        immer et al, 2016 84 247 48 246 1.74 [1.28; 2.37]        immer et al, 2018(venurafenib) 8 192 7 192 1.14 [0.42; 3.09]        immer et al, 2016 63 42 247 78 2346 1.74 [1.28; 2.37]        immer et al, 2016 (box corafenib) 8 192 7 192 1.14 [0.42; 3.09]        immer et al, 2017 6 0.32 0.10 [0.03; 0.10]        immer et al, 2016 (box corafenib) 8 192 7 192 1.14 [0.42; 3.09]        immer et al, 2016 (box corafenib) 8 192 7 192 1.14 [0.42; 3.09]        immer et al, 2017 6 10 53 0.30 0.08 [0.30; 0.19]        iscerto et al, 2016 10 247 31 246 0.32 0.16; [0.64]        ing et al,	Subgroup = Hyperkeratosis Flaherty et al, 2012(trametinib 1mg) Flaherty et al, 2012(trametinib 2mg) Robert et al, 2015 Ascierto et al, 2016 Long et al, 2017 Dummer et al, 2018(encorafenib) Dummer et al, 2018(vemurafenib) Total (95% CI) Heterogenelty: Tau <sup>2</sup> = 0.1002; Chi <sup>2</sup> = 1	a 3 54 5 55 15 350 25 247 15 209 27 192 27 192 27 192 1299 3.74, df = 6 (P =	16 53 16 53 86 349 67 246 74 211 72 192 54 186 1290 0.03); 1 <sup>2</sup> = 56%	0.18 [0.06; 0.59] 0.30 [0.12; 0.76] 0.17 [0.10; 0.29] 0.37 [0.24; 0.57] 0.20 [0.12; 0.34] 0.38 [0.25; 0.56] 0.48 [0.32; 0.73] 0.30 [0.22; 0.41]	* * * *
$\begin{aligned} & \text{lng et al, 2017} & 11 \ 209 \ 39 \ 211 \ 0.28 \ [0.15; 0.54] \\ & \text{mmer et al, 2018(encorafenib)} \ 17 \ 192 \ 49 \ 192 \ 0.35 \ [0.21; 0.58] \\ & \text{mmer et al, 2018(encorafenib)} \ 17 \ 192 \ 29 \ 186 \ 0.57 \ [0.32; 1.00] \\ & \text{tal (95% CI)} \ 593 \ 589 \ 0.39 \ [0.26; 0.57] \\ & \text{tal errogeneity: Tau2 = 0.0330; Chi2 = 2.83, df = 2 (P = 0.24); l2 = 29% \\ & \text{tal group = Skin papilloma} \\ & \text{aherty et al, 2012(trametinib 1mg)} \ 4 \ 54 \ 8 \ 53 \ 0.49 \ [0.16; 1.53] \\ & \text{tal aherty et al, 2012(trametinib 2mg)} \ 2 \ 55 \ 8 \ 53 \ 0.24 \ [0.05; 1.08] \\ & \text{bort et al, 2012(trametinib 2mg)} \ 2 \ 55 \ 8 \ 53 \ 0.24 \ [0.05; 1.08] \\ & \text{tal geometre tal, 2018(encorafenib)} \ 12 \ 192 \ 18 \ 192 \ 0.67 \ [0.33; 1.35] \\ & \text{mmer et al, 2018(encorafenib)} \ 12 \ 192 \ 18 \ 192 \ 0.67 \ [0.33; 1.35] \\ & \text{tarmmer et al, 2018(encorafenib)} \ 12 \ 192 \ 18 \ 192 \ 0.67 \ [0.33; 1.35] \\ & \text{tarmmer et al, 2018(encorafenib)} \ 12 \ 192 \ 18 \ 192 \ 0.67 \ [0.33; 1.35] \\ & tareogeneity: Tau2 = 0.6167; Chi2 = 21.79, df = 5 (P < 0.01); l2 = 77\% \\ & \text{tareogeneity: Tau2 = 0.6167; Chi2 = 21.79, df = 5 (P < 0.01); l2 = 77\% \\ & \text{tareogeneity: Tau2 = 1.1904; Chi2 = 71.73, df = 4 (P < 0.01); l2 = 94\% \\ & \text{tareogeneity: Tau2 = 1.1904; Chi2 = 71.73, df = 4 (P < 0.01); l2 = 94\% \\ & \text{tareogeneity: Tau2 = 1.1904; Chi2 = 71.73, df = 4 (P < 0.01); l2 = 94\% \\ & \text{tareogeneity: Tau2 = 1.1904; Chi2 = 71.73, df = 4 (P < 0.01); l2 = 94\% \\ & \text{tareogeneity: Tau2 = 1.1904; Chi2 = 71.73, df = 4 (P < 0.01); l2 = 94\% \\ & \text{tareogeneity: Tau2 = 1.1904; Chi2 = 71.79, df = 4 (P < 0.01); l2 = 94\% \\ & \text{tareogeneity: Tau2 = 0.2957; Chi2 = 7.99, df = 4 (P = 0.09); l2 = 95\% \\ & \text{tareogeneity: Tau2 = 0.2957; Chi2 = 7.99, df = 4 (P = 0.09); l2 = 50\% \\ & \text{tareogeneity: Tau2 = 0.2957; Chi2 = 7.99, df = 4 (P = 0.09); l2 = 50\% \\ & \text{tareogeneity: Tau2 = 0.2957; Chi2 = 7.99, df = 4 (P = 0.09); l2 = 50\% \\ & \text{tareogeneity: Tau2 = 0.2957; Chi2 = 7.99, df = 4 (P = 0.$	Subgroup = Palmoplantar erythro Robert et al, 2015 Dummer et al, 2018(encorafenib) Dummer et al, 2018(vemurafenib) Total (95% Cl) Heterogeneity: Tau <sup>2</sup> = 0.3847; Chi <sup>2</sup> = 1	dysaesthesia 14 350 13 192 13 192 734 0.29, df = 2 (P <	<b>87 349</b> 98 192 26 186 727 0.01); I <sup>2</sup> = 81%	0.16 [0.09; 0.28] 0.13 [0.08; 0.23] 0.48 [0.26; 0.91] 0.21 [0.10; 0.47]	# # ◆
ubgroup = Skin papilloma         aherty et al, 2012(trametinib 2mg)       4       54       8       53       0.49 [0.16; 1.53]         aherty et al, 2012(trametinib 2mg)       2       55       8       53       0.24 [0.05; 1.08]         bbert et al, 2015       6       350       80       349       0.07 [0.03; 0.17]         ing et al, 2017       5       209       46       211       0.11 [0.04; 0.27]         immer et al, 2018(encorafenib)       12       192       31       186       0.38 [0.20; 0.71]         interogeneity: Tau <sup>2</sup> = 0.6167; Chi <sup>2</sup> = 21.79, df = 5 (P < 0.01); l <sup>2</sup> = 77%       1052       1044       0.25 [0.12; 0.52]         ibgroup = Photosensitivity reaction       0       27       192       1.14 [0.42; 3.09]         ing et al, 2017       6       209       6       211       1.01 [0.33; 3.08]         ing et al, 2018(encorafenib)       8       192       7       192       1.14 [0.42; 3.09]         intra (95% Cl)       1190       1184       0.56 [0.20; 1.54]       0.56 [0.20; 1.54]         tat (95% Cl)       1190       1184       0.56 [0.20; 1.54]       0.56 [0.20; 1.54]         tat (95% Cl)       1190       1184       0.56 [0.20; 1.54]       0.56 [0.20; 1.54] <td< td=""><td>Subgroup = Palmoplantar kerator Long et al, 2017 Dummer et al, 2018(encorafenib) Dummer et al, 2018(vemurafenib) Total (95% Cl) Heterogeneity: Tau<sup>2</sup> = 0.0330; Chi<sup>2</sup> = 2</td><td>lerma 11 209 17 192 17 192 593 .83, df = 2 (P = 0</td><td>39 211 49 192 29 186 589 0.24); I<sup>2</sup> = 29%</td><td>0.28 [0.15; 0.54] 0.35 [0.21; 0.58] 0.57 [0.32; 1.00] 0.39 [0.26; 0.57]</td><td>*</td></td<>	Subgroup = Palmoplantar kerator Long et al, 2017 Dummer et al, 2018(encorafenib) Dummer et al, 2018(vemurafenib) Total (95% Cl) Heterogeneity: Tau <sup>2</sup> = 0.0330; Chi <sup>2</sup> = 2	lerma 11 209 17 192 17 192 593 .83, df = 2 (P = 0	39 211 49 192 29 186 589 0.24); I <sup>2</sup> = 29%	0.28 [0.15; 0.54] 0.35 [0.21; 0.58] 0.57 [0.32; 1.00] 0.39 [0.26; 0.57]	*
abgroup = Photosensitivity reaction         bert et al, 2015       13       350       78       349       0.17       [0.9; 0.29]         sciento et al, 2016       84       247       48       246       1.74       [1.28; 2.37]         nmmer et al, 2017       6       209       6       211       1.01       [0.33; 3.08]         nmmer et al, 2018(vemurafenib)       8       192       7       192       1.14       [0.42; 3.09]         atd (95% CI)       1190       1184       0.56       [0.20; 1.54]         terogeneity: Tau <sup>2</sup> = 1.1904; Chl <sup>2</sup> = 71.73, df = 4 (P < 0.01); l <sup>2</sup> = 94%       455       10       53       0.10 [0.01; 0.74]         aherty et al, 2012(trametinib 2mg)       4       55       10       53       0.39 [0.13; 1.15]         obert et al, 2016       10       247       31       246       0.32 [0.16; 0.64]         ing et al, 2017       3       209       10       211       0.30 [0.08; 1.08]         itat (95% CI)       915       912       0.21 [0.11; 0.42]       4         itat (95% CI)       915       912       0.21 [0.11; 0.42]       4         itat (95% CI)       915       912       0.21 [0.11; 0.42]       4         itat (95%	Subgroup = Skin papilloma Flaherty et al, 2012(trametinib 1mg) Flaherty et al, 2012(trametinib 2mg) Robert et al, 2015 Long et al, 2017 Dummer et al, 2018(encorafenib) Dummer et al, 2018(vemurafenib) Total (95% Cl) Heterogeneity: Tau <sup>2</sup> = 0.6167; Chi <sup>2</sup> = 2	4 54 2 55 6 350 5 209 12 192 12 192 1052 1.79, df = 5 (P <	8 53 8 53 80 349 46 211 18 192 31 186 1044 0.01); I <sup>2</sup> = 77%	0.49 [0.16; 1.53] 0.24 [0.05; 1.08] 0.07 [0.03; 0.17] 0.11 [0.04; 0.27] 0.67 [0.33; 1.35] 0.38 [0.20; 0.71] 0.25 [0.12; 0.52]	+ + + +
Jubgroup = Cutaneous squamous-cell carcinoma         aherty et al, 2012(trametinib 1mg)       1       54       10       53       0.10       [0.01; 0.74]         aherty et al, 2012(trametinib 2mg)       4       55       10       53       0.39       [0.13; 1.15]         bert et al, 2015       5       350       63       349       0.08       [0.03; 0.19]         science et al, 2016       10       247       31       246       0.32       [0.16; 0.64]         ing et al, 2017       3       209       10       211       0.30       [0.08; 1.08]         stat (95% CI)       915       912       0.21       [0.11; 0.42]         sterogeneity: Tau <sup>2</sup> = 0.2957; Chl <sup>2</sup> = 7.99, df = 4 (P = 0.09); l <sup>2</sup> = 50%       4       247       23       246       0.17       [0.06; 0.49]         upmer et al, 2016       4       247       23       246       0.17       [0.06; 0.49]       4	Subgroup = Photosensitivity read Robert et al, 2015 Ascierto et al, 2016 Long et al, 2017 Dummer et al, 2018(encorafenib) Dummer et al, 2018(venurafenib) Total (95% Cl) Heterogeneity: Tau <sup>2</sup> = 1.1904; Chi <sup>2</sup> = 7	tion 13 350 84 247 6 209 8 192 8 192 1190 1.73, df = 4 (P <	78 349 48 246 6 211 7 192 45 186 1184 0.01); I <sup>2</sup> = 94%	0.17 [0.09; 0.29] 1.74 [1.28; 2.37] 1.01 [0.33; 3.08] 1.14 [0.42; 3.09] 0.17 [0.06; 0.36] 0.56 [0.20; 1.54]	*
ubgroup = Keratoacanthoma scierto et al, 2016 4 247 23 246 0.17 [0.06; 0.49]	Subgroup = Cutaneous squamou Flaherty et al, 2012(trametinib 1mg) Flaherty et al, 2012(trametinib 2mg) Robert et al, 2015 Ascierto et al, 2016 Long et al, 2017 Total (95% Cl) Heterogeneity: Tau <sup>2</sup> = 0.2957; Chl <sup>2</sup> = 7	s-cell carcino 1 54 4 55 5 350 10 247 3 209 915 .99, df = 4 (P = 0	$ \begin{array}{cccc} & 10 & 53 \\ & 10 & 53 \\ & 63 & 349 \\ & 31 & 246 \\ & 10 & 211 \\ & 912 \\ 0.09); \ l^2 = 50\% \end{array} $	0.10 [0.01; 0.74] 0.39 [0.13; 1.15] 0.08 [0.03; 0.19] 0.32 [0.16; 0.64] 0.30 [0.06; 1.08] 0.21 [0.11; 0.42]	* * *
The term of the control of the term of term o	Subgroup = Keratoacanthoma Ascierto et al, 2016 Dummer et al, 2018(encorafenib) Dummer et al, 2018(vemurafenib) Total (95% CI) Heterogeneity: Tau <sup>2</sup> = 0; Chi <sup>2</sup> = 0.84, d Heterogeneity: Tau <sup>2</sup> = 0.4260; Chi <sup>2</sup> = 4	4 247 4 192 4 192 631 f = 2 (P = 0.66); 74.03, df = 45 (P	$23 246$ $12 192$ $21 186$ $624$ $l^{2} = 0\%$ $< 0.01); l^{2} = 91\%$	0.17 [0.06; 0.49] 0.33 [0.11; 1.02] 0.18 [0.06; 0.53] 0.22 [0.12; 0.40]	

FIGURE 2

Overall study estimates of the risk ratio (RR) of cutaneous adverse events of all grades associated with BRAF and MEK inhibitor treatment vs. BRAF inhibitor monotherapy.

0.12–0.52; P < 0.001; I<sup>2</sup> = 77%), cutaneous squamous-cell carcinoma (RR, 0.21; 95% CI, 0.11–0.42; P < 0.001; I<sup>2</sup> = 50%), and keratoacanthoma (RR, 0.22; 95% CI, 0.12–0.40; P < 0.001; I<sup>2</sup> = 0%) (Figure 2). The RR of photosensitivity reaction were similar

between the BRAF and MEK inhibitor group and the control group (RR, 0.56; 95% CI, 0.20–1.54; p = 0.258;  $I^2 = 94\%$ ) (Figure 2).

Overall, 32.97% of patients from the BRAF and MEK inhibitor treatment group had risk of rash compared with

Study or Subgroup	Experim Events	ental Total	Co Events	ontrol Total	Risk Ra MH, Random	tio , 95% Cl	Risk Ratio MH, Random, 95% Cl
Subgroup = Cutaneous squamous	s-cell ca	rcino	na				
Robert et al. 2015	5	350	60	349	0.08 [0.03	0.201	
Flaherty et al. 2012(trametinib 1mg)	1	54	9	53	0 11 [0 01	0.831	
Elaberty et al. 2012(trametinib 2mg)	3	55	q	53	0.32 [0.09]	1 121	
Ascierto et al. 2016	a	247	31	246	0.20 [0.00,	0.501	_
	3	247	10	240	0.29 [0.14,	1 091	
	3	209	10	211	0.30 [0.08,	0.271	
Heterogeneity: Tau <sup>2</sup> = 0.1895; Chi <sup>2</sup> = 5.	.96, df = 4	915 (P = 0	.20); I <sup>2</sup> = 3	33%	0.20 [0.11;	0.37]	•
hubaroun = Pash							
Pobert et al. 2015	4	350	30	240	0 13 10 05	0 271	-
Assistant al 2016	40	247	40	246	1 05 10 70	1.551	- 1
	42	247	40	240	0.20 [0.70,	1.00]	- T
Long et al, 2017	0	209	2	211	0.20 [0.01;	4.10]	
Dummer et al, 2016(encoralemb)	2	192	4	192	0.50 [0.09,	2.70]	
Jummer et al, 2018(vemuratenib)	2	192	6	100	0.32 [0.07;	1.58]	
otal (95% CI) leterogeneity: Tau <sup>2</sup> = 0.6789; Chi <sup>2</sup> = 1	5.52, df =	1190 4 (P <	0.01); I <sup>2</sup> =	<b>1184</b> 74%	0.40 [0.15;	1.03]	-
ibgroup = Keratoacanthoma	2	247	21	246	0 14 10 04	0 471	
Nummer et al. 2019/vomureferih)	3	100	21	196	0.14 [0.04,	1 211	
	0	192	0	100	0.07 [0.00,	1.31]	
eterogeneity: Tau <sup>2</sup> = 0; Chi <sup>2</sup> = 0.17, di	f = 1 (P = 0)	<b>439</b> ).68);	<sup>2</sup> = 0%	432	0.13 [0.04;	0.39]	-
ubgroup = Palmoplantar erythro	dysaesth	iesia :	syndrom	e			
Robert et al, 2015	0	350	1	349	0.33 [0.01;	8.13]	
Dummer et al, 2018(encorafenib)	0	192	26	192	0.02 [0.00;	0.31] -	
ummer et al, 2018(vemurafenib)	0	192	2	186	0.19 [0.01;	4.01]	
otal (95% CI)		734		727	0.09 [0.02;	0.57]	
leterogeneity: Tau <sup>2</sup> = 0.2210; Chi <sup>2</sup> = 2.	.09, df = 2	(P = 0	.35); I <sup>2</sup> = -	4%			
Subgroup = Hyperkeratosis							
obert et al, 2015	0	350	2	349	0.20 [0.01;	4.14]	
scierto et al, 2016	1	247	6	246	0.17 [0.02;	1.37]	
ong et al, 2017	0	209	1	211	0.34 [0.01;	8.21]	
ummer et al. 2018(encorafenib)	1	192	7	192	0.14 [0.02]	1.151	
ummer et al. 2018(vemurafenib)	1	192	0	186	2.91 [0.12]	70,901	
otal (95% CI)		1190		1184	0.26 [0.08	0.811	
eterogeneity: $Tau^2 = 0$ ; $Chi^2 = 2.74$ , di	f = 4 (P = 0)	0.60); I	<sup>2</sup> = 0%	1104	0.20 [0.00,	0.01]	
ibaroun = Palmonlantar kerator	lorma						
abgroup - rannoplantar keratoo	1011110	200	1	211	1 01 10 06.	16 031	
ummer at al 2019(anacrafanih)		100	1	100	0.14 0.04	2 751	
Summer et al. 2018(encoratenilb)	0	192	3	192	0.14 [0.01;	2.70]	
Contract (0.5% CI)	0	192	2	186	0.19[0.01;	4.01]	
Otal ( $35\%$ CI) leterogeneity: Tau <sup>2</sup> = 0: Chi <sup>2</sup> = 1.05 d	f = 2 / D = 1	501.1	2 = 0.0%	288	0.32 [0.06;	1.73	
	(F = (	), I	- 070				
bgroup = Photosensitivity reac	tion	0.55		0.10	0.00.00.01	0.403	_
obert et al, 2015	0	350	1	349	0.33 [0.01;	8.13]	
scierto et al, 2016	8	247	0	246	16.93 [0.98;	291.74]	
ummer et al, 2018(encorafenib)	1	192	0	192	3.00 [0.12;	73.18]	
ummer et al, 2018(vemurafenib)	1	192	2	186	0.48 [0.04;	5.30]	
otal (95% CI)		981	~	973	1.63 [0.27;	9.95]	-
eterogeneity: Tau <sup>2</sup> = 1.2404; Chi <sup>2</sup> = 4.	.67, df = 3	(P = 0	.20); I <sup>2</sup> = 1	36%			
bgroup = Alopecia							
obert et al. 2015	0	350	1	349	0.33 [0.01	8,131	
scierto et al. 2016	1	247	1	246	1.00 0 00	15.831	
ong et al. 2017	1	200	0	211	3 03 10 12	73 921	
ong et al, 2017	1	209	0	211	1.00 [0.12;	5 761	
(35%  CI)	( _ 0 / D _ /	000	2 - 00/	000	1.00 [0.17;	0.10	
eterogeneity: $1au^2 = 0$ ; $Chi^2 = 0.92$ , d	T = 2 (P = (	J.63);	= 0%				
terogeneity: Iau <sup>-</sup> = 0.4618; Chi <sup>2</sup> = 6	5.14, df = 1	29 (P <	< 0.01); l <sup>2</sup>	= 55%			
			1 4 (2)				
t for subgroup differences: Chi <sup>2</sup> = 10	0.52, df = 7	(P = (	J. 10)		-		

FIGURE 3 Overall study estimates of the risk ratio (RR) of cutaneous adverse events of Grade 3 or 4 associated with BRAF and MEK inhibitor Treatment vs. BRAF inhibitor monotherapy.

38.40% in the control group, and 10.3% of patients in the BRAF and MEK treatment group developed alopecia, compared with 37.59% in the BRAF inhibitor control group. Analysis revealed

that therapy with BRAF and MEK inhibitors was associated with lower risk of all-grade hyperkeratosis than BRAF inhibitor alone, with 8.13% of patients from the BRAF and MEK inhibitors

therapy group developing hyperkeratosis compared with 29.83% of the BRAF inhibitor alone group. The proportion of patients from the BRAF inhibitor alone treatment group who had a high-grade CAE compared with the BRAF and MEK inhibitor treatment group were 29.02% vs. 4.98% for palmoplantar erythrodysaesthesia syndrome and 19.86% vs. 6.98% for palmoplantar keratoderma. 3.37% of patients from the BRAF and MEK inhibitor treatment group had a decrease in skin papilloma compared with 18.47% in BRAF inhibitor alone group. BRAF inhibitor alone was associated with a 5.2-fold increase in risk of cutaneous squamous-cell carcinoma (13.27% vs. 2.51%) and a higher risk keratoacanthoma (8.97% vs. 1.82%) than the combination of BRAF and MEK inhibitors.

#### Risk ratios of high-grade CAEs

The risk of high-grade CAEs calculated as RRs are depicted in Figure 3. Comparing with BRAF and MEK inhibitors, treatment with BRAF inhibitors alone was associated with an increased risk of hyperkeratosis (RR, 0.26; 95% CI, 0.08–0.81; p = 0.021;  $I^2 =$ 0%), palmoplantar erythrodysaesthesia syndrome (RR, 0.09; 95% CI, 0.02–0.57; p = 0.010;  $I^2 = 4\%$ ), cutaneous squamous-cell carcinoma (RR, 0.20; 95% CI, 0.11-0.37; P < 0.001; I<sup>2</sup> = 33%), and keratoacanthoma (RR, 0.13; 95% CI, 0.04-0.39; P < 0.001;  $I^2 = 0\%$ ) (Figure 3). In contrast with the risk of all-grade rash, alopecia, and palmoplantar keratoderma, the risk of high-grade rash, alopecia, palmoplantar keratoderma, and photosensitivity reaction were similar between groups (RR, 0.40; 95% CI, 0.15-1.03; p = 0.057;  $I^2 = 74\%$ ) (RR, 1.00; 95% CI, 0.17-5.76; p = 0.999; I<sup>2</sup> = 0%) (RR, 0.32; 95% CI, 0.06–1.73; p = 0.188; I<sup>2</sup> = 0%) (RR, 1.63; 95% CI, 0.27–9.95; p = 0.594;  $I^2 = 36\%$ ), respectively, (Figure 3).

Overall, 0.20% of patients from the BRAF and MEK inhibitor treatment group had a decrease in hyperkeratosis compared with 1.35% in the control group, and 0.00% of patients in the BRAF and MEK treatment group developed palmoplantar erythrodysaesthesia syndrome, compared with 3.99% in the BRAF inhibitor control group. The proportion of patients from the BRAF inhibitor alone treatment group who had a high-grade CAE compared with the BRAF and MEK inhibitor treatment group were 12.81% vs. 2.30% for cutaneous squamous-cell carcinoma and 6.25% vs. 0.68% for keratoacanthoma.

#### Heterogeneity and sensitivity analysis

The heterogeneity for each analysis of all-grade CAEs was statistically significant, except for photosensitivity reaction analyses, where heterogeneity could be rated as substantial. The heterogeneity for each analysis of high-grade CAEs was statistically significant, except for alopecia, palmoplantar keratoderma, photosensitivity reaction, and rash analyses, where heterogeneity could be rated as low.

A sensitivity analysis was performed by excluding each study in a stepwise manner from the analysis to determine the relative importance of each study. Treatment with BRAF inhibitor alone remained a risk factor for the selected outcomes.

#### Publication bias assessment

The studies were reviewed for publication bias. The risk of bias of the included studies was depicted in Figure 4.

#### Discussion

Up to now, this is the first systematic review and meta-analysis pooled 5 RCTs with 2,361 participants to present a relatively comprehensive overview of the association between CAEs in patients treated with combined BRAF and MEK inhibitors therapy or patients receiving BRAF inhibitor alone. Common combination therapies are dabrafenib and trametinib, vemurafenib and cobimetinib, and encorafenib and binimetinib. BRAF inhibitor monotherapy are dabrafenib, vemurafenib, and encorafenib. To our knowledge, this is the first study to calculate the RRs of alopecia, cutaneous squamous-cell carcinoma, hyperkeratosis, keratoacanthoma, palmoplantar erythrodysaesthesia syndrome, palmoplantar keratoderma, rash, photosensitivity reaction, and skin papilloma.

The main results of our study were as follows: (1) BRAF and MEK inhibitor therapy was associated with a lower RR of rash, alopecia, hyperkeratosis, palmoplantar erythrodysaesthesia syndrome, palmoplantar keratoderma, skin papilloma, cutaneous squamous-cell carcinoma, and keratoacanthoma compared with BRAF inhibitor monotherapy; (2) The RR of photosensitivity reaction were similar between the BRAF and MEK inhibitor therapy and BRAF inhibitor monotherapy; (3) the RRs of highgrade hyperkeratosis, palmoplantar erythrodysaesthesia syndrome, cutaneous squamous-cell carcinoma, and keratoacanthoma were lower in the group being treated with BRAF and MEK inhibitors than in the group being treated with BRAF inhibitor monotherapy. (4) In contrast with the risk of all-grade rash, alopecia, and palmoplantar keratoderma, the risk of high-grade rash, alopecia, palmoplantar keratoderma, and photosensitivity reaction were similar between the BRAF and MEK inhibitor therapy and BRAF inhibitor monotherapy.

It is interesting to note that when applying MEK inhibitors with BRAF inhibitor can reduce cutaneous toxicities, the effects that are mediated by suppression cause skin toxicity reaction of special activation of MAP kinase pathways. Cutaneous toxicities, most notably squamous cell carcinomas (SCC), are considered a mechanism-related class effect of BRAF inhibitors. The development of cutaneous toxicities of BRAF inhibitors may be explained by paradoxical activation of the MAPK pathway in wildtype BRAF cells. The formation of homo or hetero RAF dimers in wild-type BRAF cells in the presence of oncogenic RAS mutation and subsequently activation of MEK is considered the major cause for the observed cutaneous adverse effects of BRAF inhibitor (Heidorn et al., 2010; Hatzivassiliou et al., 2010). The mechanism is not only suggested by preclinical studies, it is also demonstrated by the high prevalence of oncogenic RAS mutation in clinical samples for patients who developed SCC with BRAF inhibitor treatment (Su et al., 2012; Anforth et al., 2012). Concomitant MEK inhibitor administration has improved the skin toxicity profile of BRAF inhibitor by multiple clinical studies (Robert et al., 2015; Ribas et al., 2014). Sanlorenzo et al. directly performed a retrospective



cohort study, collecting data from 44 melanoma patients treated either with BRAF inhibitors (vemurafenib or dabrafenib) or BRAF and MEK inhibitor combination regimens (vemurafenib + cobimetinib or dabrafenib + trametinib) (Sanlorenzo et al., 2014). As expected, cutaneous AEs were less frequent in patients with BRAF inhibitor and MEK inhibitor combination compared with those in patients with BRAF inhibitor alone, and cutaneous AEs occurred more frequently and faster during BRAF inhibitor therapy

than during BRAF and MEK inhibitors combination therapy among patients who received single treatment regimen (either BRAF inhibitor monotherapy or BRAF and MEK inhibitors combination treatment). In particular, they observed a longer cutaneous adverse event-free interval during treatment with a combination of dabrafenib and trametinib. Treatment with vemurafenib causes a multitude of cutaneous AEs, such as exanthema, photosensitivity, palmarplantar dysesthesia or handfoot syndrome, alopecia, pruritus, hyperkeratosis, skin papillomas, keratoacanthomas and cutaneous squamouscell carcinomas (Chapman et al., 2011; Flaherty et al., 2012b; Mattei et al., 2013). The most frequent cutaneous AEs of dabrafenib are hyperkeratosis, papilloma, alopecia, and palmar-plantar erythrodysesthesia syndrome. Trametinib is more frequently related with the development of acneiform dermatitis or alopecia (Flaherty et al., 2012a; Anforth et al., 2014). Less is known about the cutaneous AEs related to cobimetinib.

In our study, 32.97% of patients from the BRAF and MEK inhibitor treatment group had a decrease in rash compared with 38.40% in the BRAF inhibitor alone control group. Common AEs reported at a lower frequency (with a difference in proportion of patients of 10% or higher) in the encorafenib plus binimetinib group than in the encorafenib or vemurafenib groups were toxic effects to the skin (e.g., pruritus, hyperkeratosis, rash, keratosis pilaris, palmoplantar keratoderma, palmoplantar erythrodysaesthesia syndrome, dry skin, skin papilloma, macropapular rash, and sunburn), alopecia, and photosensitivity reaction (Dummer et al., 2018b). In our study, 10.3% of patients in the BRAF and MEK treatment group developed alopecia, compared with 37.59% in the BRAF inhibitor alone control group. In one study, the most frequent cutaneous AEs were rash (43%), alopecia (39%) in the vemurafenib group (Robert et al., 2015). Cutaneous effects were more frequent in the vemurafenib group than in the combination-therapy group, in particular rash (43% vs. 22%), photosensitivity reaction (22% vs. 4%), hand-foot syndrome (25% vs. 4%), skin papillomas (23% vs. 2%), squamous-cell carcinomas and keratoacanthomas (18% vs. 1%), and hyperkeratosis (25% vs. 4%) (Robert et al., 2015). Analysis revealed that therapy with BRAF and MEK inhibitors was associated with lower risk of all-grade hyperkeratosis than BRAF inhibitor alone, with 8.13% of patients from the BRAF and MEK inhibitors therapy group developing hyperkeratosis compared with 29.83% of the BRAF inhibitor alone group. The development of hyperkeratosis, a well-known precursor of cutaneous squamous cell carcinomas, was frequent during monotherapy with both BRAF inhibitors. It has be reported that the development of cutaneous squamous cell carcinomas during BRAF inhibitor therapy is caused by activation of the MAPK pathway in keratinocytes with preexisting RAS mutations commonly found in chronically sun damaged skin. The proportion of patients from the BRAF inhibitor alone treatment group who had a high-grade CAEs compared with the BRAF and MEK inhibitor treatment group were 29.02% vs. 4.98% for palmoplantar erythrodysaesthesia syndrome and 19.86% 6.98% for palmoplantar keratoderma. vs. Photosensitivity is another well-known AE experienced during vemurafenib treatment (Chapman et al., 2011; Sosman et al., 2012). Previous studies speculated that this is due to the chemical structure of the drug and ultraviolet A exposure, rather than due to BRAF inhibitor and the subsequent consequences on MAPK signaling (Dummer et al., 2012). In our experience, also, photosensitivity was more frequent in patients treated with vemurafenib. Regardless of the treatment regimen, anytime a patient receives vemurafenib, particular attention should be given to sun exposure prevention measures. From the results of this study, we conclude that clinical decision-making can be helped according to patients' history of skin-related AEs. Physicians can preferentially choose BRAF and MEK inhibitors treatment, when facing patients with better economic conditions or similar skin toxicity in the past.

## Limitations

This study has some limitations that need to be addressed. First, the double therapy regimen was compared with single therapy, and a perfect delimitation of the adverse events deriving from BRAF inhibitors or MEK inhibitors cannot be done. Second, the treatment regimens were different between the studies; although from the same class of therapies, there are some specific adverse events related to each regimen. Third, 2 study (Flaherty et al., 2012b; Dummer et al., 2018b) were analyzed as 2 separate studies, which could induce bias in the final analysis. However, excluding an arm from the final analysis did not influence the conclusion.

# Conclusion

In conclusion, therapy with BRAF and MEK inhibitors was associated with an decreased risk of CAEs, especially rash, alopecia, hyperkeratosis, palmoplantar erythrodysaesthesia syndrome, palmoplantar keratoderma, skin papilloma, cutaneous squamouscell carcinoma, and keratoacanthoma, compared with BRAF inhibitor monotherapy. The risks of photosensitivity reaction was similar between the assessed groups. These adverse events should be carefully approached in skin-oncology teams for an optimal treatment of patients with melanoma.

## Author contributions

JQ: Conceptualization, Data curation, Writing–original draft. JW: Formal Analysis, Writing–original draft, Conceptualization. QY: Software, Writing–review and editing. YC: Methodology, Software, Writing–original draft. TL: Conceptualization, Writing–review and editing. YZ: Project administration, Writing–review and editing. ZT: Methodology, Project administration, Writing–review and editing.

# Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research was supported by Suqian Sci&Tech Program (Grant No: KY202312).

# Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

## References

Anforth, R., Liu, M., Nguyen, B., Uribe, P., Kefford, R., Clements, A., et al. (2014). Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib. *Australas. J. Dermatol* 55, 250–254. doi:10.1111/ajd.12124

Anforth, R., Tembe, V., Blumetti, T., and Fernandez-Peñas, P. (2012). Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors. *Pigment. Cell Melanoma Res.* 25, 569–572. doi:10.1111/j.1755-148X.2012.01031.x

Arnold, M., Singh, D., Laversanne, M., Vignat, J., Vaccarella, S., Meheus, F., et al. (2022). Global burden of cutaneous melanoma in 2020 and projections to 2040. *JAMA Dermatol* 158, 495–503. doi:10.1001/jamadermatol.2022.0160

Ascierto, P. A., Dummer, R., Gogas, H. J., Flaherty, K. T., Arance, A., Mandala, M., et al. (2020). Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. *Eur. J. Cancer* 126, 33–44. doi:10.1016/j.ejca.2019.11.016

Ascierto, P. A., McArthur, G. A., Dreno, B., Atkinson, V., Liszkay, G., Di Giacomo, A. M., et al. (2016). Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. *Lancet Oncol.* 17, 1248–1260. doi:10.1016/S1470-2045(16)30122-X

Ascierto, P. A., Schadendorf, D., Berking, C., Agarwala, S. S., van Herpen, C. M., Queirolo, P., et al. (2013). MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. *Lancet Oncol.* 14, 249–256. doi:10.1016/S1470-2045(13)70024-X

Barrios, D. M., Phillips, G. S., Freites-Martinez, A., Hsu, M., Ciccolini, K., Skripnik Lucas, A., et al. (2020). Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study. *J. Eur. Acad. Dermatol Venereol.* 34, 1340–1347. doi:10.1111/jdv. 16159

Califano, I., Smulever, A., Jerkovich, F., and Pitoia, F. (2024). Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease. *Rev. Endocr. Metab. Disord.* 25, 123–147. doi:10. 1007/s11154-023-09833-1

Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *N. Engl. J. Med.* 364, 2507–2516. doi:10.1056/NEJMoa1103782

Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., et al. (2002). Mutations of the BRAF gene in human cancer. *Nature* 417, 949–954. doi:10.1038/ nature00766

Dummer, R., Ascierto, P. A., and Gogas, H. J. (2018a). Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial (vol 19, pg 1315, 2018). *Lancet Oncol.* 19, E509. doi:10.1016/S1470-2045(18)30497-2

Dummer, R., Ascierto, P. A., Gogas, H. J., Arance, A., Mandala, M., Liszkay, G., et al. (2018b). Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol.* 19, 603–615. doi:10.1016/S1470-2045(18) 30142-6

Dummer, R., Flaherty, K. T., Robert, C., Arance, A., de Groot, J. W. B., Garbe, C., et al. (2022). COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. *J. Clin. Oncol.* 40, 4178–4188. doi:10.1200/JCO.21. 02659

Dummer, R., Rinderknecht, J., and Goldinger, S. M. (2012). Ultraviolet A and photosensitivity during vemurafenib therapy. *N. Engl. J. Med.* 366, 480–481. doi:10. 1056/NEJMc1113752

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

## Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2024.1457226/ full#supplementary-material

Dzwierzynski, W. W. (2021). Melanoma risk factors and prevention. Clin. Plast. Surg. 48, 543–550. doi:10.1016/j.cps.2021.05.001

Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., et al. (2012b). Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. *N. Engl. J. Med.* 367, 1694–1703. doi:10.1056/NEJMoa1210093

Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., et al. (2012a). Improved survival with MEK inhibition in BRAF-mutated melanoma. *N. Engl. J. Med.* 367, 107–114. doi:10.1056/NEJMoa1203421

Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., et al. (2010). RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. *Nature* 464, 431–435. doi:10.1038/nature08833

Hauschild, A., Dummer, R., Schadendorf, D., Santinami, M., Atkinson, V., Mandalà, M., et al. (2018). Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma. *J. Clin. Oncol.* 36, 3441–3449. doi:10.1200/JCO.18.01219

Hauschild, A., Grob, J. J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., et al. (2012). Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. *Lancet* 380, 358–365. doi:10.1016/S0140-6736(12) 60868-X

Heidorn, S. J., Milagre, C., Whittaker, S., Nourry, A., Niculescu-Duvas, I., Dhomen, N., et al. (2010). Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. *Cell* 140, 209–221. doi:10.1016/j.cell.2009.12.040

Higgins, J. P. T., and Green, D. (2011). Cochrane Handb. Syst. Rev. Interventions. Available at: http://handbook-5-1.cochrane.org/(Accessed June 27, 2019).

Larkin, J., Ascierto, P. A., Dréno, B., Atkinson, V., Liszkay, G., Maio, M., et al. (2014). Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. *N. Engl. J. Med.* 371, 1867–1876. doi:10.1056/NEJMoa1408868

Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., et al. (2009). The PRISMA statement for reporting systematic reviews and metaanalyses of studies that evaluate healthcare interventions: explanation and elaboration. *Bmj* 339, b2700. doi:10.1136/bmj.b2700

Long, G. V., Eroglu, Z., Infante, J., Patel, S., Daud, A., Johnson, D. B., et al. (2018). Long-Term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib. *J. Clin. Oncol.* 36, 667–673. doi:10.1200/ JCO.2017.74.1025

Long, G. V., Flaherty, K. T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., et al. (2017). Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. *Ann. Oncol.* 28, 1631–1639. doi:10.1093/annonc/mdx176

Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., et al. (2014). Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. *N. Engl. J. Med.* 371, 1877–1888. doi:10.1056/NEJMoa1406037

Mattei, P. L., Alora-Palli, M. B., Kraft, S., Lawrence, D. P., Flaherty, K. T., and Kimball, A. B. (2013). Cutaneous effects of BRAF inhibitor therapy: a case series. *Ann. Oncol.* 24, 530–537. doi:10.1093/annonc/mds292

Planchard, D., Besse, B., Groen, H. J. M., Souquet, P. J., Quoix, E., Baik, C. S., et al. (2016). Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. *Lancet Oncol.* 17, 984–993. doi:10.1016/S1470-2045(16)30146-2

Raschi, E., Fusaroli, M., La Placa, M., Ardizzoni, A., Zamagni, C., Poluzzi, E., et al. (2022). Skin toxicities with cyclin-dependent kinase 4/6 inhibitors in breast cancer: signals from disproportionality analysis of the FDA adverse event reporting system. *Am. J. Clin. Dermatol* 23, 247–255. doi:10.1007/s40257-021-00645-0

Ribas, A., Gonzalez, R., Pavlick, A., Hamid, O., Gajewski, T. F., Daud, A., et al. (2014). Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)- mutated melanoma: a phase 1b study. Lancet Oncol. 15, 954–965. doi:10.1016/S1470-2045(14)70301-8

Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., et al. (2015). Improved overall survival in melanoma with combined dabrafenib and trametinib. *N. Engl. J. Med.* 372, 30-39. doi:10.1056/ NEJMoa1412690

Sanlorenzo, M., Choudhry, A., Vujic, I., Posch, C., Chong, K., Johnston, K., et al. (2014). Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. *J. Am. Acad. Dermatol* 71, 1102–1109. doi:10.1016/j.jaad.2014.09.002

Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., et al. (2012). Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. *N. Engl. J. Med.* 366, 707–714. doi:10.1056/NEJMoa1112302

Su, F., Viros, A., Milagre, C., Trunzer, K., Bollag, G., Spleiss, O., et al. (2012). RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. *N. Engl. J. Med.* 366, 207–215. doi:10.1056/NEJMoa1105358

Viera, A. J. (2008). Odds ratios and risk ratios: what's the difference and why does it matter? *South Med. J.* 101, 730–734. doi:10.1097/SMJ.0b013e31817a7ee4

Yélamos, O., Merkel, E. A., Sholl, L. M., Zhang, B., Amin, S. M., Lee, C. Y., et al. (2016). Nonoverlapping clinical and mutational patterns in melanomas from the female genital tract and atypical genital nevi. *J. Invest Dermatol* 136, 1858–1865. doi:10.1016/j.jid.2016. 05.094

Zhao, F., Zhu, J., Yu, R., Shao, T., Chen, S., Zhang, G., et al. (2022). Cutaneous adverse events in patients treated with PD-1/PD-L1 checkpoint inhibitors and their association with survival: a systematic review and meta-analysis. *Sci. Rep.* 12, 20038. doi:10.1038/ s41598-022-24286-3